【正文】 ntainer。 (5) colorants, preservatives, spices, flavorings or other excipients are added without authorization。 or (6) other cases where the drug standards are not conformed. Article 50 A drug name listed in the national drug standards is an adopted name in China. Such an adopted name may not be used as a trademark. Article 51 Employees of drug manufacturers, drug distributors and medical institutions who are in direct contact with drugs shall undergo health checkup annually. No one who suffers from infectious diseases or any other diseases which may cause contamination to drugs may engage in any work in direct contact with drugs. Chapter VI Control over the Packaging of Drugs Article 52 Immediate packaging materials and containers shall meet the requirements for medicinal use and the standards for ensuring human health and safety. They shall, along with the drugs, be subject to examination and approval by the drug regulatory department. No drug manufacturers may use immediate packaging materials and containers for which no approval is obtained. If the immediate packaging materials and containers are not up to standard, the drug regulatory department shall give orders stopping the use of such materials and containers. Article 53 Drug packaging shall conform to drug quality requirements and be convenient for storage, transportation and medical use. Chinese crude drugs shall be packed for transportation. On each package shall be indicated the name of the drug, the origin of production, the date of consignment and the name of the consignor, with a quality certification mark attached. Article 54 A label shall be printed on or attached to the drug package together with an insert sheet, as required by regulations. In the label or insert sheet shall be indicated the adopted name of the drug in China, its ingredients, strength, manufacturer, approval number, product batch number, production date, date of expiry, indications or functions, usage, dosage, contraindications, adverse drug reactions, and precautions. Specified marks shall be printed in the label of narcotic drugs, psychotropic substances, toxic drugs for medical use, radioactive pharmaceuticals, drugs for topical use, and nonprescription drugs. Chapter VII Control over Drug Pricing and Advertising Article 55 For drugs the prices of which are fixed or guided by the government according to law, the petent pricing department of the government shall, on the pricing principle stipulated in the Pricing Law of the People39。s Republic of China and on the basis of average social cost, supply and demand on the market, and public affordability, rationally fix and adjust the prices, in order to ensure that price is mensurate with quality, eliminate excessively high price, and protect the legitimate interests of users. Drug manufacturers, drug distributors and medical institutions shall implement prices fixed or guided by the government. No one may raise prices in any manner without authorization. Drug manufacturers shall provide the truthful manufacturing and operation cost to the petent pricing department of the government. No one may refuse to or falsely or deceptively report the cost. Article 56 For drugs the prices of which are adjustable with the market according to law, drug manufacturers, drug distributors and medical institutions shall fix the prices on the principles of fairness, rationality，good faith and mensuration of price with quality, in order to provide the users with drugs of reasonable prices. When fixing and indicating retailing prices, drug manufacturers, drug distributors and medical institutions shall abide by the regulations on control over drug prices formulated by the petent pricing department under the State Council. Usurious profits and fraud in pricing that harms the users39。 interests are prohibited. Article 57 Drug manufacturers, drug distributors and medical institutions shall provide the actual buying and selling prices and quantity of the drugs purchased and sold, and other related data to the petent pricing department of the government. Article 58 Medical institutions shall provide the patients with a list of drug prices。 and the medical institutions designated by medical insurance provider shall truthfully publicize the prices of drugs in mon use in pliance with the specified measures, in order to ensure reasonable use of drugs. Specific measures shall be formulated by the administrative department for health under the State Council. Article 59 Drug manufacturers, drug distributors and medical institutions are prohibited from offering or accepting, in private, offthebook rakeoffs or other benefits in the course of purchasing and selling drugs. Drug manufacturers, drug distributors or their agents are prohibited from offering, under any pretences, money or things of value or other benefits to leading members, drug purchasers, physicians, or other related persons of the medical institutions where their drugs are used. Leading members of medical institutions, drug purchasers, physicians, or other related persons, on their part, are prohibited from accepting, under any pretences, money or things of value or other benefits offered by drug manufacturers and drug distributors or their agents. Article 60 Drug advertisements shall be subject to approval by the drug regulatory department of the people39。s government of the province, autonomous region or municipality directly under the Central Government where the enterprise is located, an approval number of drug advertisement shall be issued. No one may launch advertisements without the approval number. Prescription drugs may be introduced in the medical or pharmaceutical professional publications jointly designated by the administrative department for health and the drug regulatory department under the State Council, but their advertisements may not be released